Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate - sprookjes - yvandenbroek - TriplyDB

Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate

Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate

http://www.wikidata.org/entity/Q24658507

about

Role of LIGHT in the pathogenesis of joint destruction in rheumatoid arthritis.Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.Assessment of Distal Radius Bone Mineral Density in Osteoporosis Patients Receiving Denosumab, Including Those with Rheumatoid Arthritis and Those Receiving Oral Glucocorticoids.Can rheumatoid arthritis ever cease to exist: a review of various therapeutic modalities to maintain drug-free remission?The Impact of Conventional and Biological Disease Modifying Antirheumatic Drugs on Bone Biology. Rheumatoid Arthritis as a Case Study.Autoimmunity as a trigger for structural bone damage in rheumatoid arthritis.Inflammatory osteolysis: a conspiracy against bone.Inflammation induces osteoclast differentiation from peripheral mononuclear cells in chronic kidney disease patients: crosstalk between the immune and bone systems.Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines.Response to: 'Denosumab, cortical bone and bone erosion in rheumatoid arthritis' by Rossini et al.Interleukin-7 Induces Osteoclast Formation via STAT5, Independent of Receptor Activator of NF-kappaB Ligand.Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.Cherubism Mice Also Deficient in c-Fos Exhibit Inflammatory Bone Destruction Executed by Macrophages That Express MMP14 Despite the Absence of TRAP+ Osteoclasts.Bone Loss in Rheumatoid Arthritis: Basic Mechanisms and Clinical Implications.Skeletal complications of rheumatoid arthritis.Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems.Repair of Bone Erosion in Rheumatoid Arthritis by Denosumab: A High-Resolution Peripheral Quantitative Computed Tomography Study.Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis.Denosumab, cortical bone and bone erosions in rheumatoid arthritis.The role of IL-23 receptor signaling in inflammation-mediated erosive autoimmune arthritis and bone remodeling.Pharmacological Therapy of Osteoporosis: A Systematic Current Review of Literature.Targeted antibody therapy and relevant novel biomarkers for precision medicine for rheumatoid arthritis.RANKL: A therapeutic target for bone destruction in rheumatoid arthritis.Titer-Dependent Effect of Anti-Citrullinated Protein Antibodies On Systemic Bone Mass in Rheumatoid Arthritis Patients.Separately tackling the development of erosions with denosumab: ultimately closing a gap in the treatment of patients with rheumatoid arthritis or trying too hard too late?Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis.The Hidden Burden of Fractures in People Living With HIV Bone erosions in rheumatoid arthritis: recent developments in pathogenesis and therapeutic implications

P2860

Q33711522-F06A9C8C-D17B-40DB-BB4B-E21C3F3579D9 Q34545263-E3DB3328-1CF1-40ED-BD99-419C006BDF84 Q37421054-BEDA1179-51E2-4C61-8445-079DA87EF42A Q38598776-FBCF9786-184B-49D4-8A60-593059E5AAFE Q38831693-A9F0313D-695F-4B8E-81F3-E27411F70340 Q39067021-6C153A63-A47A-4085-B2AA-E0ECC9B4B36F Q39343563-9A34604F-2954-4D4D-A012-9B625F2D055D Q41921500-62873A05-B15B-47B7-805E-D4A6CA30F78C Q45045554-706292D7-FE07-4F07-9976-E2CB3F5B364E Q46559560-4A2E75EE-29AE-42DC-A5C8-A02932FC8E5F Q47133316-CFA2708B-59AE-4355-84B4-4D52E470F70E Q47679545-94E48B2C-5EA2-4B3E-B6DD-D37E2694872D Q47796415-38706EEB-F25C-4DBD-A0BA-84A1A5AA0616 Q47800990-3FE718D1-1312-434D-ABC6-174765FA7951 Q47805955-D259C6D3-91E4-4B06-BF46-649DCDE7DAAC Q47944184-48225DDF-2195-4A40-BFC9-E59FCD5CA6CC Q47973046-64CEC417-138F-4564-84E0-8941A1F1D48D Q48058354-644BF0A3-E61E-4697-B8C6-C4C38E15FCFF Q48187901-CFD158CD-55FB-45CB-926F-BA11146BF20B Q48283709-529B6876-3CD1-4625-9D48-794AEED14BA7 Q49165503-F2598A74-A398-454D-A424-3091FD3AC1C0 Q50082712-CFA16D43-DBE4-47B5-BA9C-1EDC8F530157 Q50207113-104E7721-DEC4-4832-83B2-E3C24D0C755E Q51117846-D918606D-F0FB-4556-889E-C6C874A9ED1B Q51530420-F8206341-BBD2-439E-9BF9-E41D9BC63B61 Q51797784-995DC571-AE86-4EDC-B251-B1F1E23B845A Q57143538-BD1D4457-E04B-4AF9-B560-27FA95FAF1F0 Q58774487-88676267-B921-491C-9956-DDA385AA41D3

P2860

Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate

http://www.wikidata.org/entity/Q24658507

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

name

Effect of denosumab on Japanes ...... toId arthritis on methotrexate

@ast

Effect of denosumab on Japanes ...... toId arthritis on methotrexate

@en

Effect of denosumab on Japanes ...... toId arthritis on methotrexate

@nl

type

label

Effect of denosumab on Japanes ...... toId arthritis on methotrexate

@ast

Effect of denosumab on Japanes ...... toId arthritis on methotrexate

@en

Effect of denosumab on Japanes ...... toId arthritis on methotrexate

@nl

prefLabel

Effect of denosumab on Japanes ...... toId arthritis on methotrexate

@ast

Effect of denosumab on Japanes ...... toId arthritis on methotrexate

@en

Effect of denosumab on Japanes ...... toId arthritis on methotrexate

@nl

P1433

Q24658507-88D58290-C8E9-4276-90F6-6930BBE6C5A8

P1476

Q24658507-CBBA2CBD-FC82-439D-87FB-7F2B407345DE

P2093

Q24658507-15A1E1FE-5CE0-4DA9-B90A-999E97AABFCE

Q24658507-5A49C936-6F79-41B9-85BA-2B7715DE78EE

Q24658507-88E0AF4F-A51C-4071-9ED5-41BE8387E97F

Q24658507-A1BB1112-81B6-4EC8-A22E-560B9377111C

Q24658507-CBAD91A2-0D42-444C-B48C-CB31D385676B

Q24658507-CC4FC926-CDD9-481F-AACD-CADBCF3345C4

Q24658507-EE809D4A-044A-4B54-89DE-F2FDF85D244B

P2860

Q24658507-039DDC7E-B4FD-4878-9338-CBB3203A3BB2

Q24658507-0C0D40F9-1CD5-42BF-9CD7-59049B0A4320

Q24658507-314486EF-C2C1-4C0B-8F4D-6C5D549DBD98

Q24658507-384405EB-29DE-4940-AB62-58A38C0CC1D3

Q24658507-3A613C21-C23F-4B1C-9E6C-198CB74D68B6

Q24658507-3E2A8389-061A-4C49-84D8-7CE2CC2370ED

Q24658507-538A945A-7F8A-4EDB-B644-0CD1E47670FF

Q24658507-61D9BDED-ACF1-4A54-A0D0-94C6CFAF121F

Q24658507-62763115-0628-4984-B3DE-70E926F1F11F

Q24658507-69DCCEAF-8A91-42DB-8424-1C0C7FD9CF29

P304

Q24658507-A0C5BA0F-BF98-4156-8EEC-354AAD28491A

P31

Q24658507-D0DED0C5-F276-4A4A-BEBC-0D2E9DB91A40

P3181

Q24658507-038F5911-3F4F-4CBB-9D0D-F140A3423BDD

P356

Q24658507-EC76039D-6F0A-402E-9336-ADA78A514664

P407

Q24658507-8D7798EF-F40E-4E6A-A505-D16B95E3BC51

P433

Q24658507-A7FB4ED4-EB08-4DD6-B677-2E62652A4091

P478

Q24658507-378B669E-00E6-4AAB-993F-BF168E5A4837

P50

Q24658507-4A713D65-41D0-4BF6-AAD0-46794E53CD77

Q24658507-732CCF7C-6BA5-410C-8F9A-5ED0346A87E5

P577

Q24658507-3AE83A9A-9521-4061-A97E-A0C506BD602C

P5875

Q24658507-C6203AC8-438A-468C-BE40-D7DC0F8CCBC1

P698

Q24658507-AF237F4F-E6CE-46CA-9022-8B76A34DB372

P921

Q24658507-9B281399-8950-4DED-94F7-4379BA5FBAB6

P932

Q24658507-4A8443C5-B204-4DEA-92CA-3B345B1E37E5

P3181

P356

ANNRHEUMDIS-2015-208052

P1433

Annals of the Rheumatic Diseases

P1476

Effect of denosumab on Japanes ...... olled, phase II clinical trial

@en

P2093

Harry K Genant

http://www.w3.org/2001/XMLSchema#string

Hisashi Yamanaka

http://www.w3.org/2001/XMLSchema#string

Naoki Ishiguro

http://www.w3.org/2001/XMLSchema#string

Naoki Okubo

http://www.w3.org/2001/XMLSchema#string

Takeshi Ohira

http://www.w3.org/2001/XMLSchema#string

Toshiyuki Yoneda

http://www.w3.org/2001/XMLSchema#string

Yoshiya Tanaka

http://www.w3.org/2001/XMLSchema#string

P2860

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

Denosumab in postmenopausal women with low bone mineral density

In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial.

Associations of CTX-II with biochemical markers of bone turnover raise questions on its tissue origin: data from CHECK, a cohort study of early osteoarthritis.

Treating rheumatoid arthritis to target: recommendations of an international task force.

TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts.

Mechanisms of Disease: the link between RANKL and arthritic bone disease.

P304

983-990

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2882590

http://www.w3.org/2001/XMLSchema#string

P356

10.1136/ANNRHEUMDIS-2015-208052

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P50

Tsutomu Takeuchi

Désirée van der Heijde

P577

2015-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

284279325

http://www.w3.org/2001/XMLSchema#string

P698

26585988

http://www.w3.org/2001/XMLSchema#string

P921

P932

4893103

http://www.w3.org/2001/XMLSchema#string